FDA Is Listening: Adolor Cited For Downplaying REMS At Conference

A company representative's oral statement that the REMS for the gastrointestinal surgery recovery drug Entereg is "due to logistics" was unacceptable, DDMAC letter says.

More from Archive

More from Pink Sheet